Breast adenoid cystic carcinoma (AdCC), a rare type of triple-negative breast cancer, has been shown to be driven by MYB pathway activation, most often underpinned by the MYB-NFIB fusion gene. Alternative genetic mechanisms, such as MYBL1 rearrangements, have been reported in MYB -NFIB-negative salivary gland AdCCs. Here we report on the molecular characterization by massively parallel sequencing of four breast AdCCs lacking the MYB -NFIB fusion gene. In two cases, we identified MYBL1 rearrangements (MYBL1-ACTN1 and MYBL1-NFIB), which were associated with MYBL1 overexpression. A third AdCC harboured a high-level MYB amplification, which resulted in MYB overexpression at the mRNA and protein levels. RNA-sequencing and whole-genome sequencing revealed no definite alternative driver in the fourth AdCC studied, despite high levels of MYB expression and the activation of pathways similar to those activated in MYB-NFIB-positive AdCCs. In this case, a deletion encompassing the last intron and part of exon 15 of MYB, including the binding site of ERG-1, a transcription factor that may downregulate MYB, and the exon 15 splice site, was detected. In conclusion, we demonstrate that MYBL1 rearrangements and MYB amplification probably constitute alternative genetic drivers of breast AdCCs, functioning through MYBL1 or MYB overexpression. These observations emphasize that breast AdCCs probably constitute a convergent phenotype, whereby activation of MYB and MYBL1 and their downstream targets can be driven by the MYB-NFIB fusion gene, MYBL1 rearrangements, MYB amplification, or other yet to be identified mechanisms.
Introduction
Breast adenoid cystic carcinoma (AdCC) is a rare type of triple-negative breast cancer (TNBC) [i.e. oestrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative] [1, 2] . Although they differ from conventional TNBCs [1, 3] , breast AdCCs have similar molecular profiles to salivary gland AdCCs, and an identical genetic driver: the MYB-NFIB fusion gene [1, [3] [4] [5] [6] [7] , which functions through MYB overexpression resulting from the loss of microRNA-binding sites or super-enhancer translocations [5, 8] .
Salivary gland AdCCs lacking the MYB-NFIB fusion gene may harbour MYBL1 rearrangements [9] [10] [11] . MYBL1 encodes A-MYB, which has extensive homology with c-MYB (encoded by MYB) and shares downstream target genes, converging in the activation of similar downstream pathways. Consistent with this notion, salivary gland AdCCs harbouring either rearrangement show similar transcriptomic profiles [11] .
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Here, we performed a comprehensive genomic analysis of four MYB-NFIB-negative breast AdCCs, indicating that MYBL1 rearrangements and MYB amplification probably constitute alternative oncogenic drivers of this rare form of TNBC.
Materials and methods

Case selection
Four MYB-NFIB-negative breast AdCCs (Figure 1 ; supplementary material, Table S1 ) were retrieved from the authors' institutions and centrally reviewed (Supplementary materials and methods). Whole-exome sequencing (WES) data from AdCC11 and AdCC12 and three MYB-NFIB-positive AdCC controls were reported previously [3] . Patient consent was obtained where appropriate, according to the protocols approved by the local Institutional Review Boards.
Immunohistochemistry
Immunohistochemistry for ER, PR, HER2 and c-MYB (clone EP769Y) was performed as previously described [2, 3, 7] (Supplementary materials and methods, and Table S2 ).
Microdissection and nucleic acid extraction
DNA and/or RNA samples of AdCC11 and AdCC12, and of MYB-NFIB-positive controls, were extracted from fresh-frozen tissue as previously described [3, 12] ; those of AdCC34 and AdCC35 were retrieved from formalin-fixed paraffin-embedded tissue samples, following microdissection (Supplementary materials and methods).
Whole-genome and targeted capture massively parallel sequencing Tumour-normal DNA samples of AdCC11 and AdCC12 were subjected to whole-genome sequencing (WGS), and those of AdCC34 were subjected to the Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT) assay [12, 13] , which targets the entire coding regions of 410 cancer genes [12, 13] (Supplementary materials and methods, and Table S3 ). Sequencing data analyses were performed as previously described (Supplementary materials and methods). To validate the somatic mutations identified by WGS, a reanalysis of the previously reported WES results [3] 
Fluorescence in situ hybridization (FISH)
The MYB-NFIB fusion gene and MYBL1 rearrangements were evaluated by FISH in all cases, as previously described [2] (Supplementary materials and methods).
Quantitative reverse transcription polymerase chain reaction
Quantitative reverse transcription polymerase chain reaction (RT-qPCR) was performed to compare the expression levels of the 5 ′ and 3 ′ portions/exons of MYB and MYBL1, with TaqMan Assay-on-Demand, as described previously [3] , in all cases, MYB-NFIB-positive AdCC6 and AdCC8 [3] , and three breast cancer cell lines with known MYB mRNA expression levels (Supplementary materials and methods).
Gene set enrichment analysis
Expression levels determined by the use of normalized RNA-sequencing reads per kilobase of transcript per million mapped reads (RPKM) values were used for single-sample gene set enrichment analysis (ssGSEA; https://genepattern.broadinstitute.org/gp/; Supplementary materials and methods).
Results and discussion
Histopathological characteristics of MYB-NFIB-negative breast AdCCs
The four FISH-proven MYB-NFIB-negative AdCCs were of the triple-negative phenotype and did not differ histologically from MYB-NFIB-positive AdCCs ( Figure 1 ; supplementary material, Figure S1 ). c-MYB protein expression, which has been documented in AdCCs lacking the MYB-NFIB fusion gene [15] , was detected at varying levels (AdCC35, H-score 43; AdCC12, H-score 75; AdCC34, H-score 120) in all cases except AdCC11 ( Figure 1 ; supplementary material, Figure S2 ).
AdCC35 harbours a MYBL1-NFIB fusion gene and MYBL1 overexpression C-terminal regulatory domains of MYBL1 were retained, akin to what has been found for previously reported MYB or MYBL1 rearrangements [10, 11, 16] . FISH analysis with MYBL1 break-apart probes confirmed the MYBL1 rearrangement at the genomic level ( Figure 1A) , and RT-qPCR and RNA sequencing revealed differential mRNA levels of the 5 ′ and 3 ′ portions of MYBL1, consistent with gene breakage (Figure 3A, B) . MYBL1 was overexpressed as compared with MYB-NFIB-positive AdCCs [3] and the breast cancer cell lines tested, and MYB expression was low ( Figures 3A and B) . As in a previously described MYBL1-rearranged salivary gland AdCC [9] , c-MYB protein expression was observed ( Figure 1A ; supplementary material, Figure S2A AdCC11 harbours a MYBL1-ACTN1 fusion gene and MYBL1 overexpression WGS of AdCC11 revealed a low mutational burden (0.52/Mb) and lack of TP53 mutations, which are frequently found in TNBCs [17] (Figure 4A ; supplementary material, Table S4 ). RNA-sequencing of this case resulted in the identification of an in-frame MYBL1-ACTN1 fusion gene, which comprised exons partners [10, 11] , but ACTN1 has not been previously reported in this context. Consistent with these findings, FISH validated the MYBL1 rearrangement ( Figure 1B) , and RT-qPCR and RNA-sequencing analyses showed high expression levels of the 5 ′ portion of MYBL1 and low expression levels of MYB.
AdCC34 harbours MYB amplification and MYB overexpression
AdCC34, which expressed c-MYB protein and lacked the MYB-NFIB fusion gene and MYBL1 rearrangements as determined by FISH ( Figure 1C ; supplementary material, Figure S2B ), was subjected to MSK-IMPACT, and this revealed only one synonymous mutation affecting TSC2 (E392E; supplementary material, Table  S4 ) and a simple copy number profile. Importantly, however, AdCC34 harboured a focal amplification on 6q23.3 encompassing MYB ( Figure 4B ). This was confirmed by FISH [mean of 5 (range 3-10) copies of MYB per tumour cell; Figure 1C] , and found to be associated with high MYB mRNA expression levels ( Figure 3A, B) and MYB protein expression levels (supplementary material, Figure S2B ). MYB amplification has not been previously described in AdCCs of any anatomical site. Given the lack of potentially pathogenic somatic mutations and of MYB and MYBL1 rearrangements, it is plausible that MYB overexpression was the result of MYB amplification, which is a novel potential mechanism of MYB activation in breast AdCCs.
AdCC12 expresses MYB and shows a gene expression profile consistent with MYB/MYBL1 activation, despite the lack of MYB and MYBL1 rearrangements RNA-sequencing, WGS and FISH of AdCC12 revealed no fusion genes or copy number alterations affecting MYB, MYBL1, or other potential candidates ( Figures 1D  and 4C ). MYB overexpression was, however, identified by immunohistochemistry (Figure 1 ; supplementary material, Figure S2C ), RT-qPCR ( Figure 3A) and RNA-sequencing ( Figure 3B ). ssGSEA revealed that AdCC12 shared with MYBL1-rearranged AdCC35 and AdCC11 and the MYB-NFIB-positive AdCC5 similar transcriptomic profiles enriched for the MYC and NOTCH signalling pathways ( Figure 3C ). These findings suggest that MYB activation may be driven by yet additional genetic mechanisms.
WGS analysis revealed a low mutational burden (0.73/Mb). However, we identified a large deletion mapping to the last intron and portion of exon 15 of MYB (c.2170-1153_2218), encompassing the binding sites of the transcription factors ERG-1 and VDR, a DNase I hypersensitive site, and the initial portions of exon 15, including the splice site (supplementary material, Figure  S3 and Table S4 ). Upregulation of ERG-1 has been shown to result in downregulation of MYB [18] ; hence, loss of its binding site could have potentially resulted in MYB overexpression. In addition, this large deletion could account for the higher mRNA levels of the 5 ′ portion than the 3 ′ portion of MYB (Figures 3A and B) . We also identified an intronic single-nucleotide deletion within intron 1 of MYBL2 ( Figure 4C ; supplementary material, Table S4 ), affecting a locus between the promoter and promoter flanking regions (c.20 + 1403delG). MYBL2, which was highly expressed in AdCC12 (supplementary material, Figure S4 ) and has been implicated in the biology of different human malignancies by regulating the cell cycle and proliferation [19] , is the third member of the MYB-family genes, encoding B-MYB. B-MYB, however, is less closely related to either c-MYB or A-MYB than the latter two are to each other. Given that the functional impact of non-coding variants has been increasingly recognized in cancer [20] , further studies are warranted to investigate whether these MYB and/or MYBL2 alterations would be pathogenic and activate the MYB pathway akin to MYB or MYBL1 rearrangements.
Taking our findings together, we have identified MYBL1 rearrangements and MYB amplification as alternative genetic drivers of MYB-NFIB-negative breast AdCCs. Our analysis corroborates the previous findings of MYB and MYBL1 rearrangements causing overexpression of MYB and MYBL1, respectively, whereas a subset of AdCCs lack MYB/MYBL1 rearrangements but still show relatively high mRNA levels of either gene and activation of similar pathways. Moreover, we demonstrate that not only rearrangements, but also gene amplification, may be the genetic alterations resulting in MYB overexpression in breast AdCCs.
Our study has important limitations. The number of cases analysed is small, because breast MYB-NFIB-negative AdCCs are vanishingly rare. Owing to limited amounts of tissue, we could only perform a targeted massively parallel sequencing assay in AdCC34, which does not rule out the possibility of coexisting fusion genes. Despite these limitations, our data support the contention that MYB/MYBL1 activation probably constitutes the common mechanism driving breast AdCCs, to which various underlying genomic alterations may converge. Further investigation of larger cohorts of AdCCs lacking the MYB-NFIB fusion gene, MYBL1 rearrangements and MYB amplification are warranted to elucidate the drivers of AdCCs lacking these genetic alterations.
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